Evidence map›Paper›PMID 30762177›Full record

ReviewCurrent heart failure reports2019

Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart Failure Patients.

James A Mann, William T Abraham

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

James A MannDivision of Cardiovascular Medicine, Wexner Medical Center at The Ohio State University, 473 W. 12th Avenue Suite 200, Columbus, OH, 43210, USA. james.mann@osumc.edu.
William T AbrahamDivision of Cardiovascular Medicine, Wexner Medical Center at The Ohio State University, 473 W. 12th Avenue Suite 200, Columbus, OH, 43210, USA.
The Ohio State University Wexner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewDespite advances in medical therapy, heart failure with reduced ejection fraction (HFrEF) is still a leading cause of mortality, hospitalizations, and healthcare costs. In this review, we describe two novel, implantable devices for the treatment of patients with HFrEF, cardiac contractility modulation (CCM), and baroreflex activation therapy (BAT), and summarize literature regarding these devices from the last 5 years. RECENT

findingsCCM improves quality of life and functional capacity as assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, 6-min hall walk test (6MHWT) distance, New York Heart Association (NYHA) functional class, peak oxygen consumption (pVO

Indexed as

Quality of LifeBaroreflexElectric Stimulation TherapyHeart FailureHumansMyocardial ContractionStroke VolumeVentricular Function, LeftBaroreflex activation therapyCardiac contractility modulationDevice therapy for heart failure with reduced ejection fraction

Identifiers

PMID30762177
OpenAlexW2914464715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.